期刊文献+

活血化瘀、血流、生物力药理学与预防医学 被引量:3

原文传递
导出
摘要 "活血化瘀"从《黄帝内经》时代就成为中医药治疗原则中的重要组成部分.在中药、针灸、按摩、锻炼等方式治疗及调理手段中,亦均以调节气血运行为核心内容.基于中医的基础理论,结合生物力学及药理学,提出了一门新的交叉学科,即生物力药理学.从血液流变学角度考察,血瘀证多表现为血流剪应力低下,而"活血化瘀"的重要内涵就是调整与适度提高血流剪应力,以达到多方面调节血管内皮细胞功能的生物效应.生物力药理学可诠释与指导中医"血脉流通,病不得生"的思路,为防治心脑血管疾病开辟一条新的途径.
作者 韩东 廖福龙
出处 《科学通报》 CAS CSCD 北大核心 2012年第20期1906-1910,共5页 Chinese Science Bulletin
基金 国家自然科学基金(90209055 10672192 90709054)资助
  • 相关文献

参考文献33

  • 1Pennisi E. How did cooperative behavior evolve. Science, 2005, 309: 93.
  • 2Copley A L. The history of clinical hemorheology. Clin Hemorheol, 1985, 5: 765-811.
  • 3Muller S, Labrador V, Da Isla N, et al. From hemorheology to vascular mechanobiology: An overview. Clin Hemorheol Microcirc, 2004, 30: 185-200.
  • 4Chiu J J, Chien S. Effects of disturbed flow on vascular endothelium: Pathophysiological basis and clinical perspectives. Physiol Rev, 2011, 91: 327-387.
  • 5Krizanac-Bengez L, Mayberg M R, Janigro D. The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology. Neurol Res, 2004, 26: 846-853.
  • 6Wang Y X, Miao H, Li S, et al. Interplay between integrins and FLK-1 in shear stress-induced signaling. Am J Physiol Cell Physiol, 2002, 283: C1540-C1547.
  • 7Wang Y X, Chang J, Li Y C, et al. Shear stress and VEGF activate IKK via the Flk-1/Cbl/Akt signaling pathway. Am J Physiol Heart Circ Physiol, 2004, 286: H685-H692.
  • 8Wang Y, Chang J, Chen K D, et al. Selective adapter recruitment and differential signaling networks by VEGF vs. shear stress. Proc Natl Acad Sci USA, 2007, 104: 8875-8879.
  • 9王阶 陈可冀 等.血瘀证诊断标准的研究[J].中西医结合杂志,1988,8(10):585-585.
  • 10廖福龙,韩东,欧阳志钢,孙云旭,马万云.衰逝波探测川芎嗪与剪应力对内皮细胞膜PS异位的影响[J].生物物理学报,2003,19(1):92-96. 被引量:6

二级参考文献31

  • 1史大卓,李静,马晓昌,张群豪,毛节明,陈明哲,陈可冀.血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察[J].中医杂志,1997,38(1):27-29. 被引量:61
  • 2中国中西医结合研究会活血化瘀专业委员会.血瘀证诊断标准[J].中西医结合杂志,1987,(3):129-129.
  • 3王阶.血瘀证诊断标准的研究[A].见:陈可冀主编.活血化瘀研究与临床[C].北京:北京医科大学中国协和医科大学联合出版社,1993.7.
  • 4中国中西医结合学会心血管病学会.冠心病中医诊断标准.中西医结合杂志,1991,11(5):257-257.
  • 5Rayn TJ,Faxon DP,Gunnar RM,et al.Guidelines for percutaneous transluminal coronary angioplasty:A report of the American College of Cardiology American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).J Am Coll Cardiol 1988; 12:529.
  • 6Ellis SG,Vandormael MG,Cowley M J,et al.Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease.Implications for patient selection.Circulation 1999 ;82:1193.
  • 7Degertekin M,Serruys PW,Foley DP,et al.Persistant inhi bition of neointimal hyperplasia after sirolimus-eluting stent implantation:long term (up to 2 years) clinical,angiographic,and intravascular ultrasound follow-up.Circulation 2002; 106:1610-1613.
  • 8Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med 2002; 346:1773-1780.
  • 9Waksman R.Drug-eluting stents:from bench to bed.Cardiovasc Radiat Med 2002; 3 (3-4):226-241.
  • 10Froeschl M,Olsen S,Ma X,et al.Current understanding of in-stent restenosis and the potential benefit of drug eluting stents.Curt Drug Targets Cardiovasc Haematol Disord 2004;4(1):103-117.

共引文献266

同被引文献52

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部